|
Table 1: Cases distribution for sex, age and suspected drug
|
1. |
Table 2: Medications reported as responsible of Pityriasi Rosea-like eruptions
|
Medication |
Main References |
|
¥
ACE-inhibitors |
¥ Wilkin JK, et al. Arch
Dermatol 1980; 116: 902-5. ¥ Steckelings UM, et al.
Acta Derm Venereol 2001; 81: 321-5. ¥ Wilkin JK, et al. Arch
Dermatol 1982; 118: 186-7. ¥ Ghersetich I, et al. G
Ital Dermatol Venereol 1990; 125: 457-9. ¥ Atzori L, et al. J Eur
Acad Dermatol Venereol 2004; 18: 743-5. |
|
¥
NSAIDs |
¥ Corke CF, et al. Br J
Rheumatol 1983; 22: 187-8. ¥ Yosipovitch G, et al. Harefuah 1993; 124: 198-200. ¥ Wolf R, et al.
Dermatologica 1985; 171: 355-6. |
|
¥
Omeprazole |
¥ Buckley C. Br J Dermatol
1996; 135: 660-1. |
|
¥
Metronidazole |
¥ Maize JC, et al. Arch
Dermatol 1977; 113: 1457-8. |
|
¥
Isotretinoin |
¥ Helfman RJ, et al. Cutis
1984; 33: 297-300. |
|
¥
Gold
salts |
¥ Bonnetblanc JM. Presse Med
1996; 25: 1555-8. |
|
¥
Imatinib
mesylate |
¥ Konstantopoulos K, et al.
Dermatology 2002; 205: 172-3. |
|
Interferon ¥
|
¥ Durusoy C, et al. J Dermatol
1999; 26: 225-8. |
|
¥
Arsenic
compounds ¥
Barbiturates
¥
Bismuth ¥
Beta-blockers ¥
Clonidine ¥
Griseofulvin ¥
Meprobamate ¥
Penicillin |
¥ Stulberg DL, et al. Am Fam
Physician 2004; 69: 87-92. ¥ Litt JZ. Pocketbook of drug
eruptions and interactions. The Parthenon Publishing Group Inc. New York,
1999 |
|
¥
Vaccine |
¥ De Keyser F, et al. Clin Exp
Rheumatol 2000;18:81-5. ¥ Honl BA, et al. Cutis
1996;57:447-50. ¥ Kaplan B, et al. Isr J Med
Sci 1989;25:570-2. |
|
Information from references 1 through 20. |
|